Orexigen (OREX) Pops Higher on Analyst Upgrade; Volatility Up

Orexigen Therapeutics (Nasdaq: OREX) is ripping higher out of the gate Thursday, following positive late-day news tied to Arena Pharma's (Nasdaq: ARNA) lorcaserin weight-loss drug Wednesday. JPMorgan upgraded the stock to Overweight earlier.

Volatility is up 77.5 percent with shares about 12 percent positive on the session early.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• This restaurant stock represents a solid risk/reward: UBS
• Midera Food Processing and Centrus Energy to join S&P SmallCap 600
• Citi highlights hidden humanoid upside in this stock’s valuation